Reply to "Comment on 'Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark'"

J Am Acad Dermatol. 2021 Dec;85(6):e359-e360. doi: 10.1016/j.jaad.2019.02.019. Epub 2019 Feb 13.

Authors

Sidsel Arnspang Pedersen¹, Anton Pottegård²

Affiliations

¹ Department of Clinical Biochemistry and Clinical Pharmacology, Odense University Hospital, Odense, Denmark; Department of Clinical Pharmacology and Pharmacy, University of Southern Denmark, Odense, Denmark. Electronic address: sarnspang@health.sdu.dk.
² Department of Clinical Pharmacology and Pharmacy, University of Southern Denmark, Odense, Denmark.

PMID: 30771416
DOI: 10.1016/j.jaad.2019.02.019

No abstract available

Publication types

Letter
Comment

MeSH terms

Case-Control Studies
Denmark / epidemiology
Humans
Hydrochlorothiazide* / adverse effects
Skin Neoplasms* / chemically induced
Skin Neoplasms* / epidemiology

Substances

Hydrochlorothiazide